Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...

New research identifies diabetes as an independent predictor of major adverse cardiovascular events in patients with both ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type ...

Ozempic, which is prescribed for certain adults with type 2 diabetes, can cause side effects. Learn about its potential side effects and how to manage them.